|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZMYM5 |
Gene summary for ZMYM5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZMYM5 | Gene ID | 9205 |
| Gene name | zinc finger MYM-type containing 5 | |
| Gene Alias | HSPC050 | |
| Cytomap | 13q12.11 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9UJ78 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9205 | ZMYM5 | LZE4T | Human | Esophagus | ESCC | 2.83e-18 | 5.80e-01 | 0.0811 |
| 9205 | ZMYM5 | LZE7T | Human | Esophagus | ESCC | 2.79e-05 | 2.90e-01 | 0.0667 |
| 9205 | ZMYM5 | LZE20T | Human | Esophagus | ESCC | 9.32e-04 | 1.04e-01 | 0.0662 |
| 9205 | ZMYM5 | LZE22T | Human | Esophagus | ESCC | 1.85e-04 | 2.96e-01 | 0.068 |
| 9205 | ZMYM5 | LZE24T | Human | Esophagus | ESCC | 4.37e-04 | 3.04e-01 | 0.0596 |
| 9205 | ZMYM5 | LZE6T | Human | Esophagus | ESCC | 4.48e-04 | 2.03e-01 | 0.0845 |
| 9205 | ZMYM5 | P1T-E | Human | Esophagus | ESCC | 6.07e-06 | 3.22e-01 | 0.0875 |
| 9205 | ZMYM5 | P2T-E | Human | Esophagus | ESCC | 3.69e-33 | 5.81e-01 | 0.1177 |
| 9205 | ZMYM5 | P4T-E | Human | Esophagus | ESCC | 2.04e-22 | 5.51e-01 | 0.1323 |
| 9205 | ZMYM5 | P5T-E | Human | Esophagus | ESCC | 1.97e-11 | 2.21e-01 | 0.1327 |
| 9205 | ZMYM5 | P8T-E | Human | Esophagus | ESCC | 8.23e-18 | 2.87e-01 | 0.0889 |
| 9205 | ZMYM5 | P9T-E | Human | Esophagus | ESCC | 2.17e-14 | 3.14e-01 | 0.1131 |
| 9205 | ZMYM5 | P10T-E | Human | Esophagus | ESCC | 3.28e-32 | 5.86e-01 | 0.116 |
| 9205 | ZMYM5 | P11T-E | Human | Esophagus | ESCC | 1.34e-17 | 7.43e-01 | 0.1426 |
| 9205 | ZMYM5 | P12T-E | Human | Esophagus | ESCC | 1.45e-18 | 3.64e-01 | 0.1122 |
| 9205 | ZMYM5 | P15T-E | Human | Esophagus | ESCC | 2.41e-29 | 6.82e-01 | 0.1149 |
| 9205 | ZMYM5 | P16T-E | Human | Esophagus | ESCC | 5.62e-38 | 6.93e-01 | 0.1153 |
| 9205 | ZMYM5 | P17T-E | Human | Esophagus | ESCC | 1.14e-03 | 3.08e-01 | 0.1278 |
| 9205 | ZMYM5 | P19T-E | Human | Esophagus | ESCC | 6.39e-06 | 4.79e-01 | 0.1662 |
| 9205 | ZMYM5 | P20T-E | Human | Esophagus | ESCC | 2.47e-18 | 4.92e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZMYM5 | SNV | Missense_Mutation | novel | c.437N>T | p.Thr146Ile | p.T146I | Q9UJ78 | protein_coding | tolerated_low_confidence(0.12) | benign(0.012) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| ZMYM5 | SNV | Missense_Mutation | c.1847C>T | p.Ser616Leu | p.S616L | Q9UJ78 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR | |
| ZMYM5 | SNV | Missense_Mutation | c.343N>A | p.Glu115Lys | p.E115K | Q9UJ78 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.984) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZMYM5 | SNV | Missense_Mutation | rs114493699 | c.854N>A | p.Arg285Gln | p.R285Q | Q9UJ78 | protein_coding | tolerated(0.22) | benign(0.005) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZMYM5 | SNV | Missense_Mutation | c.1424G>A | p.Cys475Tyr | p.C475Y | Q9UJ78 | protein_coding | tolerated_low_confidence(0.14) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZMYM5 | SNV | Missense_Mutation | novel | c.17T>C | p.Val6Ala | p.V6A | Q9UJ78 | protein_coding | tolerated_low_confidence(0.08) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZMYM5 | SNV | Missense_Mutation | rs754542115 | c.418G>A | p.Glu140Lys | p.E140K | Q9UJ78 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.89) | TCGA-3L-AA1B-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZMYM5 | SNV | Missense_Mutation | c.1273N>G | p.Lys425Glu | p.K425E | Q9UJ78 | protein_coding | tolerated(0.16) | benign(0.142) | TCGA-AA-3681-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ZMYM5 | SNV | Missense_Mutation | rs764475563 | c.1435N>G | p.Thr479Ala | p.T479A | Q9UJ78 | protein_coding | tolerated_low_confidence(0.42) | benign(0) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| ZMYM5 | SNV | Missense_Mutation | novel | c.1786T>C | p.Phe596Leu | p.F596L | Q9UJ78 | protein_coding | deleterious_low_confidence(0.05) | benign(0.003) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |